Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 98 peer-reviewed journal articles Updated
Oncology

Understanding Your DLBCL Diagnosis

At a Glance

Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive, fast-growing non-Hodgkin lymphoma. However, this rapid growth makes the cancer cells highly vulnerable to chemotherapy. It is a potentially curable disease, with 50% to 70% of patients achieving a full cure with standard treatments.

Hearing the word “aggressive” in a medical diagnosis can be deeply unsettling. It is natural to feel a sense of urgency or fear when you are told you have a fast-moving cancer. However, in the world of lymphoma, “aggressive” has a specific meaning that carries a silver lining: because the cancer cells are dividing so quickly, they are often more vulnerable to the treatments designed to stop them [1][2].

What is DLBCL?

Diffuse Large B-Cell Lymphoma (DLBCL) is a type of cancer that starts in your B-cells, which are white blood cells that normally help your body fight infections [1]. It is the most common form of aggressive non-Hodgkin lymphoma (NHL) [3].

While it is a serious diagnosis, it is not a rare one. Because it is common, doctors have a well-established “roadmap” for how to treat it. DLBCL is considered heterogeneous, meaning it can look and behave differently from person to person based on its genetic makeup [1][4].

The Meaning of “Aggressive”

In a medical context, aggressive refers to the proliferation rate, or how fast the tumor cells are multiplying [5][6].

  • Rapid Growth: These cells do not “rest”; they are constantly dividing [6].
  • Treatment Target: Most chemotherapy drugs work by attacking cells while they are in the process of dividing. Because DLBCL cells are almost always dividing, the chemotherapy has many more “targets” to hit compared to slower-growing, “indolent” lymphomas [2].
  • Urgency: Because the disease moves fast, your care team will also move fast. You may feel like everything—from your biopsy to your first treatment—is happening at a whirlwind pace. This speed is a deliberate strategy to stay ahead of the cancer [7].

Facts About Curability

DLBCL is considered a potentially curable disease [8]. This distinguishes it from some slower-growing lymphomas that can be managed for years but are difficult to fully eliminate.

  • Standard Success Rates: With standard modern treatments, approximately 50% to 70% of patients achieve a full cure [8].
  • Advancing Treatments: Researchers are constantly finding ways to improve these odds. Newer combinations and targeted therapies are showing even better results for certain high-risk groups [9][10].

Why Subtypes Matter

Your doctor may mention “cell-of-origin” or specific genetic markers. These details help the team understand exactly what kind of DLBCL you have:

  • GCB vs. ABC: These are the two main molecular subtypes. They describe which stage of development the B-cell was in when it became cancerous [1][11].
  • Double-Hit Lymphoma: This refers to specific chromosomal changes that can make the lymphoma more resistant to standard treatment, requiring a more intensive approach [12][13].

Navigating This Guide

This guide is designed to help you understand your diagnosis and treatment options.

01

Mapping Your Disease: Diagnosis and Staging

Learn how Diffuse Large B-Cell Lymphoma (DLBCL) is diagnosed and staged. Understand excisional biopsies, PET/CT scans, and what a Stage IV diagnosis means.

02

Decoding Your Pathology Report

Learn how to read your DLBCL pathology report. Understand CD20 status, cell of origin (GCB vs ABC), FISH testing, and what double-hit means for treatment.

03

Understanding Your Prognosis and IPI Score

Learn how doctors use the International Prognostic Index (IPI) to estimate your DLBCL prognosis. Understand the 5 key factors, LDH levels, and risk scores.

04

Your First-Line Treatment Options

Learn about first-line treatment options for Diffuse Large B-Cell Lymphoma (DLBCL), including R-CHOP, Pola-R-CHP, and DA-EPOCH-R. Understand side effects.

05

When the First Treatment Doesn't Work

Learn about treatment options for relapsed or refractory DLBCL. Understand how CAR-T cell therapy and bispecific antibodies work to fight returning lymphoma.

06

Life After DLBCL Treatment

Learn what to expect during life after DLBCL treatment. Understand your survivorship care plan, follow-up schedules, heart monitoring, and managing scanxiety.

Common questions in this guide

What does it mean if my DLBCL is called "aggressive"?
In lymphoma, 'aggressive' means the cancer cells are dividing and multiplying very quickly. While this sounds scary, it actually means the cancer is highly vulnerable to chemotherapy, which is specifically designed to attack fast-dividing cells.
Is diffuse large B-cell lymphoma curable?
Yes, DLBCL is considered a potentially curable disease. With standard modern treatments, approximately 50% to 70% of patients achieve a full cure, and newer therapies are continuing to improve these outcomes.
What is the difference between GCB and ABC subtypes in DLBCL?
GCB and ABC are the two main molecular subtypes of DLBCL. They indicate the specific stage of development the B-cell was in when it became cancerous. Knowing your subtype helps your care team understand how your specific lymphoma might behave.
What does it mean if I have double-hit lymphoma?
Double-hit lymphoma refers to a specific type of DLBCL with multiple chromosomal changes, often involving MYC and BCL2 or BCL6 genes. This type can be more resistant to standard treatments and usually requires a more intensive therapeutic approach.
What are 'B symptoms' and should I watch out for them?
'B symptoms' are specific warning signs of lymphoma that include unexplained fevers, drenching night sweats, and unintentional weight loss. You should monitor for these symptoms and report them to your oncologist immediately.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my cell-of-origin subtype (GCB or ABC), and does this change my treatment plan?
  2. 2.Was my biopsy tested for 'double-hit' or 'triple-hit' genetic markers like MYC, BCL2, or BCL6?
  3. 3.What is my International Prognostic Index (IPI) score, and what does it tell us about my outlook?
  4. 4.Because this is a fast-growing lymphoma, how quickly do we need to start my first round of chemotherapy?
  5. 5.Are there specific symptoms, like 'B symptoms,' that I should be monitoring and reporting to you immediately?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.

    Liu Y, Barta SK

    American journal of hematology 2019; (94(5)):604-616 doi:10.1002/ajh.25460.

    PMID: 30859597
  2. 2

    Genomic landscape of mature B-cell non-Hodgkin lymphomas - an appraisal from lymphomagenesis to drug resistance.

    Panda D, Das N, Thakral D, Gupta R

    Journal of the Egyptian National Cancer Institute 2022; (34(1)):52 doi:10.1186/s43046-022-00154-z.

    PMID: 36504392
  3. 3

    Spontaneous resolution of untreated diffuse large B-cell lymphoma of maxillary bone after incisional biopsy.

    Flatow-Trujillo L, Win K, Jencks A, et al.

    Clinical case reports 2019; (7(11)):2082-2086 doi:10.1002/ccr3.2408.

    PMID: 31788256
  4. 4

    Genetic alterations and their clinical implications in DLBCL.

    Miao Y, Medeiros LJ, Li Y, et al.

    Nature reviews. Clinical oncology 2019; (16(10)):634-652 doi:10.1038/s41571-019-0225-1.

    PMID: 31127191
  5. 5

    Primary large B-cell lymphoma of the patella with early systemic progression: A case report.

    Ben Rejeb S, Ben Romdhane M, Sghaier M, Charfi M

    International journal of surgery case reports 2025; (131()):111344 doi:10.1016/j.ijscr.2025.111344.

    PMID: 40279991
  6. 6

    Inflammatory Presentation of a Primary Extranodal Diffuse Large B-cell Lymphoma of the Maxillary Sinus.

    Cerqueira É, Colino M, Almeida R, et al.

    Cureus 2023; (15(4)):e38008 doi:10.7759/cureus.38008.

    PMID: 37223174
  7. 7

    Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma.

    Chien HC, Morreall D, Patil V, et al.

    Future oncology (London, England) 2021; (17(4)):411-422 doi:10.2217/fon-2020-0522.

    PMID: 33115291
  8. 8

    Diffuse large B-cell lymphoma: R-CHOP failure-what to do?

    Coiffier B, Sarkozy C

    Hematology. American Society of Hematology. Education Program 2016; (2016(1)):366-378 doi:10.1182/asheducation-2016.1.366.

    PMID: 27913503
  9. 9

    Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

    Morschhauser F, Salles G, Sehn LH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(35)):3698-3705 doi:10.1200/JCO-25-00925.

    PMID: 40991874
  10. 10

    Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.

    Zhao P, Zhao S, Huang C, et al.

    Hematological oncology 2025; (43(1)):e70017 doi:10.1002/hon.70017.

    PMID: 39641321
  11. 11

    Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A.

    Sun S, Wang H, Ji M

    Technology in cancer research & treatment 2019; (18()):1533033819892256 doi:10.1177/1533033819892256.

    PMID: 31829105
  12. 12

    [Diffuse large B-cell lymphoma with concomitant c-MYC and BCL6 gene rearrangements with primary skin involvement: A case report and a review of literature].

    Gabeeva NG, Koroleva DA, Belyaeva AV, et al.

    Terapevticheskii arkhiv 2017; (89(7)):85-92 doi:10.17116/terarkh201789785-92.

    PMID: 28766546
  13. 13

    Lymphoblastic lymphoma with a triple-hit profile: a rare but distinct and relevant entity.

    Hiemcke-Jiwa LS, Leguit RJ, van der Veken LT, et al.

    Human pathology 2017; (63()):171-176 doi:10.1016/j.humpath.2016.11.002.

    PMID: 27867103

This page provides educational information about DLBCL diagnoses and terminology. It is not intended as a substitute for professional medical advice from your oncologist or hematologist.

Get notified when new evidence is published on Diffuse large B-cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.